Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series. (4th July 2017)

• Record Type: Journal Article
• Authors: Kuo, Karen Y.; Kwong, Bernice; Rahman, Zakia
• Is Part Of: Journal of cosmetic and laser therapy. Volume 19:Number 5(2017:Oct.)
• Page Start: 300
• Page End: 302
• Publication Date: 2017-07-04
• Subjects: Adverse cutaneous eruptions -- alexandrite -- EGFR inhibitor -- intense pulsed light -- pulse dye laser; Skin -- Laser surgery -- Periodicals; Surgery, Plastic -- Periodicals; 617.477
• DOI: 10.1080/14764172.2017.1299187
• Languages: English
• ISSNs: 1476-4172

Abstract

ABSTRACT: The advent of targeted chemotherapy has led to the emergence of new dermatologic toxicities. We sought to use lasers and light devices to treat recalcitrant cutaneous adverse effects related to cancer treatment. Three stage III or IV cancer patients with cutaneous complications due to epidermal growth factor receptor (EGFR) inhibitors were treated with melanin and vascular-specific laser and light technologies. Two patients reported reduction in papulopustular eruption following pulse dye laser (PDL) treatment. Two patients noted reduction in hair growth following intense pulsed light (IPL) and/or Alexandrite laser treatments. One patient was treated with both the PDL and IPL and reported improvement of both EGFR-induced hypertrichosis and papulopustular eruption. Laser and light devices targeting melanin and hemoglobin can be utilized to mitigate the cutaneous adverse effects associated with EGFR inhibitors in patients who have failed traditional therapies. This represents a new option for the cancer patient who is suffering from chemotherapy-induced side effects.